fda compounding semaglutide crackdown october 2025 proposes a new GLP-1 September 2, 2025: U.S. compounding

An animal study on gut microbial composition revealed significant -diversity differences between chronic unpredictable mild stress (CUMS) rats and control rats (Meng et al., 2025), which aligns with observational findings (McGuinness et al., 2022)

GLP-1 receptor agonistslike semaglutideare prescription medicines that mimic this hormone (1)

It is not clear whether resolution of collagen, preservation of capillaries, or both contributed to Type I fiber regrowth, but the in vitro experiments support the idea that ExerVs indirectly facilitated fiber recovery

Participants assigned to the 1 mg maintenance group started at 1 mg and stayed there